- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:18 | Universal Ibogaine Inc: Universal Ibogaine has no material changes | 14 | Stockwatch | ||
| Mo | Universal Ibogaine Inc.: Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process | 2 | TheNewswire | ||
| 03.01. | Universal Ibogaine Inc: Universal Ibogaine debt matures; MCTO in effect | 7 | Stockwatch | ||
| UNIVERSAL IBOGAINE Aktie jetzt für 0€ handeln | |||||
| 03.01. | Universal Ibogaine Inc.: Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process | 2 | TheNewswire | ||
| 19.12.25 | Universal Ibogaine Inc.: Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process | 5 | TheNewswire | ||
| 03.12.25 | Universal Ibogaine Inc.: Universal Ibogaine advises further on application for Management Cease Trade Order | 8 | TheNewswire | ||
| 26.11.25 | Universal Ibogaine Inc: Universal Ibogaine applies for MCTO | 8 | Stockwatch | ||
| 25.11.25 | Universal Ibogaine Inc.: Universal Ibogaine Advises of Filing Application for Management Cease Trade Order | 4 | TheNewswire | ||
| 28.10.25 | Universal Ibogaine Inc: Universal Ibogaine "temporarily" closes Kelburn | 19 | Stockwatch | ||
| 28.10.25 | Universal Ibogaine Inc.: Universal Ibogaine Provides Corporate Update | 11 | TheNewswire | ||
| 24.09.25 | Universal Ibogaine Inc: Universal Ibogaine board lists five directors | 32 | Stockwatch | ||
| 23.09.25 | Universal Ibogaine Inc.: Universal Ibogaine Announces Board Changes | 11 | TheNewswire | ||
| 15.09.25 | Universal Ibogaine Inc: Universal Ibogaine shareholders vote down two matters | 4 | Stockwatch | ||
| 15.09.25 | Universal Ibogaine Inc.: Universal Ibogaine Announces Results of the Annual Meeting of Shareholders | 15 | TheNewswire | ||
| 05.09.25 | Universal Ibogaine Inc. provides update on intent to file Clinical Trial Application with Health Canada and confirms securing of Ibogaine drug supply | 17 | TheNewswire | ||
| 04.09.25 | Universal Ibogaine Inc: Universal Ibogaine adds Killebrew, Wagner as directors | 14 | Stockwatch | ||
| 03.09.25 | Universal Ibogaine Inc.: Universal Ibogaine advises of appointment of two new Board Members | 4 | TheNewswire | ||
| 10.04.25 | XFRA JC4: WIEDERAUFNAHME/RESUMPTION | 374 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 04.02.25 | XFRA JC4: AUSSETZUNG/SUSPENSION | 449 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILUNIVERSAL IBOGAINE... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOFI | 78,20 | -1,04 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi mit einem Kursziel von 95 Euro auf "Neutral" belassen. Die Franzosen setzten auf starkes Umsatzwachstum zum Patenauslauf... ► Artikel lesen | |
| CANOPY GROWTH | 1,034 | +2,78 % | Warum Aktien aus dem Bereich medizinisches Cannabis vor einem Comeback stehen könnten. Canopy Growth, Bioxyne und Tilray im Fokus. | ||
| ASTRAZENECA | 156,80 | -2,76 % | Schnellere Krebstherapien: AstraZeneca übernimmt KI-Firma und will Krebsforschung revolutionieren | © Foto: Marcus Brandt/dpaAstraZeneca setzt auf KI: Mit der Übernahme von Modella AI will der Pharmakonzern die Entwicklung neuer Krebstherapien und klinische Studien vorantreiben.Das Unternehmen AstraZeneca... ► Artikel lesen | |
| INNOCAN PHARMA | 4,940 | -0,80 % | INNOCAN PHARMA CORPORATION: Strukturelle Ruhe, klare Linie | ||
| ZOETIS | 104,84 | -0,96 % | Dividendenbekanntmachungen (20.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BLACKROCK ENHANCED GLOBAL DIVIDEND TRUST US0925011050 0,0827 USD 0,071 EUR BLACKROCK TECHNOLOGY AND PRIVATE EQUITY ... US09260Q1085 0... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,60 | -2,21 % | JPM26: Tryngolza set to become first wholly owned Ionis blockbuster | ||
| HAPPY BELLY FOOD GROUP | 1,170 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Yolks Breakfast Announces Grand Opening of Its First Quebec Location in Montreal | Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| CSPC PHARMA | 1,061 | -0,89 % | CSPC PHARMA (01093): INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025 | ||
| ALTIMMUNE | 3,630 | -0,60 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,005 | -1,53 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 18,000 | 0,00 % | BlackRock legt 6,94-prozentige Beteiligung an Avadel Pharmaceuticals offen | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative... ► Artikel lesen | |
| ELANCO ANIMAL HEALTH | 21,215 | +1,34 % | Elanco Secures USDA Approval For Befrena, Expands Dermatology Portfolio | WASHINGTON (dpa-AFX) - Elanco Animal Health Inc. (ELAN) announced that the U.S. Department of Agriculture (USDA) has approved Befrena (tirnovetmab), a new anti-IL31 monoclonal antibody injection... ► Artikel lesen | |
| ONO PHARMACEUTICAL | 12,600 | +3,28 % | Ono Pharma Taiwan Receives Additional Approval Of Opdivo In Combination With Ipilimumab | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical Co. announced that Ono Pharma Taiwan Co., a Taiwanese subsidiary of Ono, received the additional approval of Opdivo Intravenous Infusion... ► Artikel lesen | |
| IANTHUS CAPITAL | 0,001 | 0,00 % | iAnthus Capital Holdings, Inc.: iAnthus Reports Third Quarter 2025 Financial Results | NEW YORK and TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company") (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis... ► Artikel lesen |
UNIVERSAL IBOGAINE INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,003 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UNIVERSAL IBOGAINE INC finden Sie auf Wallstreet Online.